Pharma Mar, S.A. (BME:PHM)

Market Cap	1.39B
Revenue (ttm)	179.28M
Net Income (ttm)	34.01M
Shares Out	17.21M
EPS (ttm)	1.95
PE Ratio	41.32
Forward PE	26.55
Dividend	0.80 (0.97%)
Ex-Dividend Date	Jun 25, 2025

Volume	2,895
Average Volume	38,132
Open	80.10
Previous Close	80.60
Day's Range	80.00 - 80.55
52-Week Range	65.00 - 105.80
Beta	0.35
RSI	55.29
Earnings Date	Feb 28, 2026

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PHM

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.